What is Sudo Biosciences?
Founded in 2020, Sudo Biosciences operates as a specialized biopharmaceutical entity dedicated to the discovery and development of novel therapeutic solutions. Headquartered in Menlo Park, California, the company focuses on high-impact medical research, leveraging advanced scientific methodologies to address chronic and debilitating conditions. By maintaining a lean, high-intellect organizational structure, Sudo Biosciences has effectively bridged the gap between early-stage laboratory discovery and scalable clinical development, establishing itself as a key player in the modern biotech ecosystem.
How much funding has Sudo Biosciences raised?
Sudo Biosciences has raised a total of $184M across 2 funding rounds:
Series A
$37M
Series B
$147M
Series A (2022): $37M, investors not publicly disclosed
Series B (2024): $147M led by Dementia Discovery Fund, TPG, Surveyor Capital, Frazier Life Sciences Management, Eventide Asset Management, Sanofi Ventures, and Enavate Sciences
Key Investors in Sudo Biosciences
Dementia Discovery Fund
A specialized venture capital firm managed by SV Health Investors that focuses exclusively on developing novel therapeutics for dementia and related neurodegenerative conditions.
TPG
A global alternative asset management firm with a diversified portfolio that partners with businesses to drive long-term value creation across multiple industries.
Frazier Life Sciences Management
A prominent biotech investment firm that utilizes both venture and public strategies to build companies focused on developing novel therapeutics and medical innovation.
What's next for Sudo Biosciences?
With the successful closure of its latest financing round, Sudo Biosciences is well-positioned to expand its clinical trial footprint and enhance its internal R&D capabilities. The strategic focus will likely shift toward accelerating the transition of its lead candidates through the regulatory pipeline, while simultaneously exploring potential partnerships to broaden its therapeutic reach. As the company matures, the emphasis will remain on maintaining the high-integrity research standards that have attracted top-tier institutional backing, ensuring that its pipeline remains competitive in an increasingly crowded global market for innovative medicine.
See full Sudo Biosciences company page
